Myomo, INC Form 4 insider transactions

Harry Kovelman, Chief Medical Officer of Myomo, Inc., reports acquisition and disposal of common stock, including a sale to cover income taxes on vested restricted stock units.

Paul Gudonis, CEO of Myomo, Inc., reports the acquisition of 6,708 shares of common stock through a grant of restricted stock units that vested immediately.

David Henry, CFO of Myomo, Inc., reports the acquisition and disposal of common stock related to restricted stock units.

Micah Mitchell, Chief Commercial Officer of Myomo, Inc., reports acquisition and disposal of common stock related to vested restricted stock units.

Paul R. Gudonis, CEO of Myomo, Inc., exercised stock options at a price of $0.048 per share on February 13, 2025.

Micah Mitchell, Chief Commercial Officer of Myomo, Inc., reports the vesting and subsequent earning of performance-based restricted stock units.

Myomo's Chief Financial Officer, David Henry, acquired 3,012 shares of common stock through the vesting of performance-based restricted stock units.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., reports the vesting of performance-based restricted stock units.

Myomo CEO Paul Gudonis acquired 6,024 shares of common stock through the vesting of performance-based restricted stock units.

Myomo CEO Paul Gudonis was granted 130,000 restricted stock units, which vest over three years starting June 5, 2025, according to a recent SEC filing.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., sold 121 shares of common stock on November 4, 2024, to cover income taxes due on vesting of restricted stock units.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., sold 121 shares of common stock on October 3, 2024, to cover income taxes due on vesting of restricted stock units.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., sold 6,700 shares of common stock at an average price of $3.7586 on September 5, 2024.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., reported the sale of 2,029 shares of common stock at an average price of $4.012 on September 3, 2024, and a further transaction on September 4, 2024, to cover income taxes.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., reports the disposition of 128 shares of common stock to cover income taxes from a restricted stock unit vesting.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., disposed of shares to cover income taxes resulting from a restricted stock unit vesting.

Micah Mitchell, Chief Commercial Officer of Myomo, Inc., amended a previous SEC filing to correctly classify a transaction as a disposition of shares to cover income taxes from vesting restricted stock units.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., amended a previous SEC filing to correct the coding of a transaction involving the disposition of 5,347 shares of common stock to cover income taxes.

Micah Mitchell, Chief Commercial Officer of Myomo, Inc., sold 15,500 shares of common stock on July 1, 2024, to cover income taxes from a restricted stock unit vesting.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., sold shares to cover income taxes resulting from the vesting of a restricted stock unit grant.

David A. Henry, CFO of Myomo, Inc., sold 25,436 shares of common stock on July 1, 2024, to cover income taxes resulting from the vesting of a restricted stock unit grant.

David Henry, CFO of Myomo, Inc., sold 10,620 shares of common stock on June 10, 2024, to cover income taxes resulting from the vesting of restricted stock units.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., sold 5,347 shares of common stock on June 10, 2024, to cover income taxes resulting from vesting of restricted stock units.

Micah Mitchell, Chief Commercial Officer of Myomo, Inc., sold 6,837 shares of common stock on June 10, 2024, to cover income taxes resulting from the vesting of restricted stock units.

David A. Henry, CFO of Myomo, Inc., was granted 70,000 restricted stock units (RSUs) on June 5, 2024, which vest annually over three years starting June 5, 2025.

Micah Mitchell, Chief Commercial Officer of Myomo, Inc., was granted 50,000 restricted stock units (RSUs) on June 5, 2024, which vest annually over three years starting June 5, 2025.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., was granted 53,000 shares of common stock in the form of Restricted Stock Units.

Myomo CEO Paul Gudonis was granted 130,000 restricted stock units (RSUs) on June 5, 2024, which vest annually over three years starting June 5, 2025.

Director Thomas F. Kirk received a grant of 12,034 restricted stock units in Myomo, Inc.

Director Morris Milton Mayo reported acquiring 12,034 shares of Myomo, Inc. common stock through a grant of Restricted Stock Units.